Skip to main content
Clinical Trials/CTRI/2021/06/034375
CTRI/2021/06/034375
Completed
Phase 4

on-Interventional Observational Study Assessing Safety And Efficacy Of Neutralizing Monoclonal Antibody (Casirivimab/ Imdevimab) Treatment In A Real-World-Setting Of Mild/Moderate Covid-19 Patients In India

Roche Products India Pvt Ltd0 sites200 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Sponsor
Roche Products India Pvt Ltd
Enrollment
200
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
December 9, 2021
Last Updated
3 years ago
Study Type
Observational

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. confirmed covid\-19 infection
  • 2\. Does not require oxygen
  • 3\. Symptoms are mil/moderate
  • 4 At high risk for sever Covid 19 infection

Exclusion Criteria

  • 1\. hospitalized due to COVID\-19
  • 2\. Require oxygen therapy due to Covid\-19
  • 3\. Require an increase in baseline oxygen flow rate due to Covid\-19

Outcomes

Primary Outcomes

Not specified

Similar Trials